BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalrymple MB, Jaeger WC, Eidne KA, Pfleger KD. Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes. J Biol Chem 2011;286:16726-33. [PMID: 21378163 DOI: 10.1074/jbc.M111.223537] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
2 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
3 Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 2014;8:57. [PMID: 24834023 DOI: 10.3389/fnins.2014.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
4 Armstrong SP, Seeber RM, Ayoub MA, Feldman BJ, Pfleger KD. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V). PLoS One 2013;8:e65885. [PMID: 23762448 DOI: 10.1371/journal.pone.0065885] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
5 Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry 2013;52:8246-60. [PMID: 24144388 DOI: 10.1021/bi401119m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
6 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
7 Jaeger WC, Armstrong SP, Hill SJ, Pfleger KD. Biophysical Detection of Diversity and Bias in GPCR Function. Front Endocrinol (Lausanne) 2014;5:26. [PMID: 24634666 DOI: 10.3389/fendo.2014.00026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
8 Jaeger WC, Seeber RM, Eidne KA, Pfleger KD. Molecular determinants of orexin receptor-arrestin-ubiquitin complex formation. Br J Pharmacol 2014;171:364-74. [PMID: 24206104 DOI: 10.1111/bph.12481] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
10 Loiseau C, Casciato A, Barka B, Cayetanot F, Bodineau L. Orexin Neurons Contribute to Central Modulation of Respiratory Drive by Progestins on ex vivo Newborn Rodent Preparations. Front Physiol 2019;10:1200. [PMID: 31611806 DOI: 10.3389/fphys.2019.01200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Boularan C, Kamenyeva O, Cho H, Kehrl JH. Resistance to inhibitors of cholinesterase (Ric)-8A and Gαi contribute to cytokinesis abscission by controlling vacuolar protein-sorting (Vps)34 activity. PLoS One 2014;9:e86680. [PMID: 24466196 DOI: 10.1371/journal.pone.0086680] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
12 Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, Ventura S, Ayoub MA, Pfleger KD. Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem 2012;287:12952-65. [PMID: 22371491 DOI: 10.1074/jbc.M111.322834] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
13 Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KD. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. Br J Pharmacol 2016;173:3028-37. [PMID: 26317175 DOI: 10.1111/bph.13316] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]